---
title: "Yunnan Baiyao Group Co.,Ltd. (000538.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000538.SZ.md"
symbol: "000538.SZ"
name: "Yunnan Baiyao Group Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T19:42:45.811Z"
locales:
  - [en](https://longbridge.com/en/quote/000538.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000538.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000538.SZ.md)
---

# Yunnan Baiyao Group Co.,Ltd. (000538.SZ)

## Company Overview

Yunnan Baiyao Group Co.,Ltd engages in the sale of pharmaceuticals, medicinal materials, health and daily chemical products in China. The company offers health products; traditional Chinese medicine used for pain management and anti-inflammation, including the Yunnan Baiyao aerosol, Yunnan Baiyao ointment, and Yunnan Baiyao band-aid; generic drugs and natural specialty medicines in various areas, such as physical fitness, respiratory ailments, cardiovascular health, gynecology, pediatrics, and others; medical devices; tea products; and pharmaceutical supply chain service solutions. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.yunnanbaiyao.com.cn](https://www.yunnanbaiyao.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.35)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.61% |  |
| Net Profit YoY | 5.50% |  |
| P/B Ratio | 2.16 |  |
| Dividend Ratio | 5.12% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 90660939893.45 |  |
| Revenue | 41908301213.73 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 12.69% | B |
| Profit Margin | 12.53% | B |
| Gross Margin | 30.63% | C |
| Revenue YoY | 4.61% | C |
| Net Profit YoY | 5.50% | C |
| Total Assets YoY | 4.06% | C |
| Net Assets YoY | 3.37% | C |
| Cash Flow Margin | 89.71% | C |
| OCF YoY | 4.61% | C |
| Turnover | 0.76 | B |
| Gearing Ratio | 25.31% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Yunnan Baiyao Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "5.50%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.16",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "5.12%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "90660939893.45",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "41908301213.73",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "12.69%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "12.53%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "30.63%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "4.61%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "5.50%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.06%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.37%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "89.71%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "4.61%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.76",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "25.31%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.27 | 29/215 | 20.09 | 19.50 | 19.18 |
| PB | 2.16 | 94/215 | 2.54 | 2.51 | 2.45 |
| PS (TTM) | 2.16 | 42/215 | 2.51 | 2.48 | 2.44 |
| Dividend Yield | 5.11% | 9/215 | 4.95% | 4.16% | 3.92% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-30T16:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 67% |
| Overweight | 4 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 50.88 |
| Highest Target | 82.20 |
| Lowest Target | 64.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000538.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000538.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000538.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000538.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**